Rate, risk factors, and clinical outcomes of SARS-CoV-2 reinfection vs. primary infection in readmitted COVID-19 patients in Iran: a retrospective cohort study.
| Autor: | Shahrbaf M; Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran., Alimohamadi Y; Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran., Yousefi Arfaei R; Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran., Salesi M; Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran., Izadi M; Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran., Raei M; Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in public health [Front Public Health] 2024 Oct 17; Vol. 12, pp. 1480805. Date of Electronic Publication: 2024 Oct 17 (Print Publication: 2024). |
| DOI: | 10.3389/fpubh.2024.1480805 |
| Abstrakt: | Background: Corona Virus Disease 2019 (COVID-19) has severely impacted global health, resulting in high morbidity and mortality, and overwhelming healthcare systems, particularly in Iran. Understanding reinfection is crucial as it has significant implications for immunity, public health strategies, and vaccine development. This study aims to identify rate and the risk factors associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) reinfection and compare the clinical course of initial infection versus reinfection in readmitted COVID-19 patients in Iran. Methods: This retrospective cohort study was conducted from January 2020 to the end of 2022 in five hospitals in Iran. The study compared demographic and clinical data, vaccination status, and clinical outcomes between patients with reinfection (defined as a positive PCR test for SARS-CoV-2 at least 90 days after the primary admission) and a control group (patients who had an initial confirmed SARS-CoV-2 infection but were not readmitted with a positive PCR test for SARS-CoV-2 at least 90 days after their primary infection). Risk factors for reinfection were evaluated using a regression model. Propensity score matching (PSM) was used to compare post-clinical and laboratory outcomes between the matched case and control groups. Results: Out of 31,245 patients, 153 (0.49%) experienced reinfections. The reinfection rate was significantly higher during B.1.617.2 and B.1.1.529 variant wave ( p < 0.001). After multivariable regression analysis, incomplete vaccination status (OR: 1.68, 95% CI: 1.34-2.31, p = 0.021) and lack of booster vaccination (OR: 2.48, 95% CI: 1.96-3.65, p = 0.001) were the risk factors for reinfection. Furthermore, reinfection was associated with atypical COVID-19 symptoms, and shorter ICU and hospital stays ( p < 0.001). The B.1.1.529 variant was significantly more common among reinfected patients ( p < 0.001). Conclusion: SARS-CoV-2 reinfections are more frequently observed during waves of novel variants and are associated with a milder clinical course and shorter hospital stays. Full vaccination and booster doses can effectively reduce the risk of SARS-CoV-2 reinfections. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Shahrbaf, Alimohamadi, Yousefi Arfaei, Salesi, Izadi and Raei.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|